DE3561198D1 - Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications - Google Patents
Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complicationsInfo
- Publication number
- DE3561198D1 DE3561198D1 DE8585301809T DE3561198T DE3561198D1 DE 3561198 D1 DE3561198 D1 DE 3561198D1 DE 8585301809 T DE8585301809 T DE 8585301809T DE 3561198 T DE3561198 T DE 3561198T DE 3561198 D1 DE3561198 D1 DE 3561198D1
- Authority
- DE
- Germany
- Prior art keywords
- spiro
- indenes
- naphthalenes
- dihydro
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59301284A | 1984-03-23 | 1984-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3561198D1 true DE3561198D1 (en) | 1988-01-28 |
Family
ID=24372993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8585301809T Expired DE3561198D1 (en) | 1984-03-23 | 1985-03-15 | Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0159143B1 (enExample) |
| JP (1) | JPS60209572A (enExample) |
| KR (1) | KR850006188A (enExample) |
| AU (1) | AU563668B2 (enExample) |
| CA (1) | CA1244443A (enExample) |
| DE (1) | DE3561198D1 (enExample) |
| DK (1) | DK131885A (enExample) |
| ES (1) | ES8606295A1 (enExample) |
| FI (1) | FI851170A7 (enExample) |
| GR (1) | GR850704B (enExample) |
| HU (1) | HU195783B (enExample) |
| IL (1) | IL74667A (enExample) |
| PH (1) | PH23921A (enExample) |
| PL (1) | PL145198B1 (enExample) |
| PT (1) | PT80145B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4575507A (en) * | 1985-05-29 | 1986-03-11 | Pfizer Inc. | Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use |
| GB2355264A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
| AU2004222328B2 (en) | 2003-03-14 | 2009-10-08 | Merck Sharp & Dohme Corp. | Aryl spirohydantoin CGRP receptor antagonists |
| AU2005285083B2 (en) * | 2004-09-13 | 2011-03-10 | Merck Sharp & Dohme Corp. | Tricyclic anilide spirohydantoin CGRP receptor antagonists |
| CA2629406A1 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirohydantoin aryl cgrp receptor antagonists |
| CN111732545B (zh) * | 2020-06-08 | 2023-03-10 | 华侨大学 | 一种2,3-二氢螺[咪唑-4,1′-茚]类化合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117230A (en) * | 1976-10-18 | 1978-09-26 | Pfizer Inc. | Hydantoin derivatives as therapeutic agents |
| US4130714A (en) * | 1977-05-23 | 1978-12-19 | Pfizer Inc. | Hydantoin therapeutic agents |
| US4181729A (en) * | 1979-03-21 | 1980-01-01 | Pfizer Inc. | Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives |
| US4226875A (en) * | 1979-04-02 | 1980-10-07 | Pfizer Inc. | Novel spiro-oxazolidinediones |
| ES8400116A1 (es) * | 1981-10-13 | 1983-10-16 | Pfizer | "un procedimiento por analogia para la preparacion de derivados de espiro-oxindol-oxazolidindiona". |
| ZA832679B (en) * | 1982-05-07 | 1983-12-28 | Ici Plc | Indoline derivatives |
| US4556670A (en) * | 1982-12-06 | 1985-12-03 | Pfizer Inc. | Spiro-3-hetero-azolones for treatment of diabetic complications |
-
1985
- 1985-03-15 DE DE8585301809T patent/DE3561198D1/de not_active Expired
- 1985-03-15 EP EP85301809A patent/EP0159143B1/en not_active Expired
- 1985-03-19 PH PH32003A patent/PH23921A/en unknown
- 1985-03-20 GR GR850704A patent/GR850704B/el unknown
- 1985-03-20 IL IL74667A patent/IL74667A/xx unknown
- 1985-03-21 PL PL1985252487A patent/PL145198B1/pl unknown
- 1985-03-21 CA CA000477079A patent/CA1244443A/en not_active Expired
- 1985-03-21 KR KR1019850001848A patent/KR850006188A/ko not_active Ceased
- 1985-03-21 ES ES541450A patent/ES8606295A1/es not_active Expired
- 1985-03-21 PT PT80145A patent/PT80145B/pt unknown
- 1985-03-22 FI FI851170A patent/FI851170A7/fi not_active Application Discontinuation
- 1985-03-22 AU AU40251/85A patent/AU563668B2/en not_active Ceased
- 1985-03-22 JP JP60057640A patent/JPS60209572A/ja active Pending
- 1985-03-22 HU HU851108A patent/HU195783B/hu not_active IP Right Cessation
- 1985-03-22 DK DK131885A patent/DK131885A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HU195783B (en) | 1988-07-28 |
| HUT37603A (en) | 1986-01-23 |
| FI851170A0 (fi) | 1985-03-22 |
| FI851170L (fi) | 1985-09-24 |
| JPS60209572A (ja) | 1985-10-22 |
| DK131885A (da) | 1985-09-24 |
| ES8606295A1 (es) | 1986-04-16 |
| GR850704B (enExample) | 1985-07-19 |
| DK131885D0 (da) | 1985-03-22 |
| CA1244443A (en) | 1988-11-08 |
| FI851170A7 (fi) | 1985-09-24 |
| PL252487A1 (en) | 1985-10-08 |
| PH23921A (en) | 1990-01-23 |
| ES541450A0 (es) | 1986-04-16 |
| IL74667A0 (en) | 1985-06-30 |
| PT80145B (en) | 1987-03-23 |
| AU4025185A (en) | 1985-09-26 |
| EP0159143B1 (en) | 1987-12-16 |
| IL74667A (en) | 1988-12-30 |
| AU563668B2 (en) | 1987-07-16 |
| PT80145A (en) | 1985-04-01 |
| PL145198B1 (en) | 1988-08-31 |
| KR850006188A (ko) | 1985-10-02 |
| EP0159143A1 (en) | 1985-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU580820B2 (en) | Treatment of obesity | |
| PL254699A1 (en) | Tobacco treatment method | |
| GB8512061D0 (en) | Effluent treatment | |
| GB8500353D0 (en) | Skin treatment composition | |
| GB8614300D0 (en) | Treatment of tobacco | |
| GB8419516D0 (en) | Treatment | |
| GB8419515D0 (en) | Treatment | |
| AU581672B2 (en) | Novel treatment | |
| GB8412049D0 (en) | Treatment | |
| GB2198942B (en) | Therapeutic composition for diabetic complications | |
| GB8501959D0 (en) | Treatment of tobacco | |
| IL74667A0 (en) | Spiro-indenes and spiro-1,2-dihydronaphthalenes for treatment of diabetic complications | |
| DE3379043D1 (en) | Spiro-3-hetero-azolones for treatment of diabetic complications | |
| ZA839023B (en) | Spiro-3-hetero-azolones for treatment of diabetic complications | |
| AU7683381A (en) | Treatment of diabetes with biolin (vitamin-h) | |
| AU538406B3 (en) | Hair treatment | |
| GB8421539D0 (en) | Treatment of tobacco | |
| PH17726A (en) | Treatment for diabetic complications | |
| ZA829106B (en) | Treatment for diabetic complications | |
| GB8504905D0 (en) | Treatment of glaucoma | |
| ZA85174B (en) | Skin treatment composition | |
| GB8400461D0 (en) | Skin treatment composition | |
| GB8408174D0 (en) | Skin treatment composition | |
| GB8510810D0 (en) | Treatment of diabetes mellitus | |
| GB8419517D0 (en) | Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |